Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer

PURPOSE: Neoadjuvant chemoimmunotherapy (nCIT) is becoming a new therapeutic frontier for resectable esophageal squamous cell carcinoma (ESCC); however, crucial details and technical know-how regarding surgical techniques and the perioperative challenges following nCIT remain poorly understood. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Baihua, Zhao, Hongbo, Wu, Xun, Gong, Lianghui, Yang, Desong, Li, Xu, Chen, Xiaoyan, Li, Jigang, Wang, Wenxiang, Wu, Jie, Xiao, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941171/
https://www.ncbi.nlm.nih.gov/pubmed/36825006
http://dx.doi.org/10.3389/fimmu.2023.1066527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941171/
https://www.ncbi.nlm.nih.gov/pubmed/36825006
http://dx.doi.org/10.3389/fimmu.2023.1066527

Ejemplares similares